Ncardia - Stem Cell Provider
Our collaboration partner Ncardia is offering iPSC-derived cells for Assays on Nanion's Instruments
Ncardia believes that stem cell technology will help to get better medicines to patients faster. Ncardia develops produces & commercialises highly predictive human cellular assay systems for safety and efficacy testing. The cardiac product portfolio encompasses a broad panel of hiPSC-derived cardiac and neural cell types. In addition, the company delivers the Cardioplate™ product line of quality controlled ready to use assay plates. Ncardia delivers working assay solutions & extensive support.
The following cells were validated on Nanion's Instruments:
In order to translate an in vitro cardiac cellular model into the correct clinical interpretation of assay read-outs, a fully functional and validated model is needed. This is assured by all of our cardiomyocytes which are fully functional human iPSC-derived cardiomyocytes produced under a stringent quality manufacturing system.
CardioPlate™ is a product line of pre-seeded hiPSC-derived cardiomyocytes (Pluricyte® Cardiomyocytes) on different plate formats. These plates are ready-to-use for a variety of different assays for predictive safety pharmacology, toxicity testing and efficacy screening early in drug discovery and development.
Ncardia’s neural cell portfolio offers 3 relevant cell types that can be used for different structural and functional toxicity assays and CNS disease modeling. All our neural cells have been validated in different morphological and electrophysiological assays. Below you can find an overview of our neural cell types derived from human induced pluripotent stem cells (hiPSC).